Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$43,155 Mln
Revenue (TTM)
$2,300 Mln
Net Profit (TTM)
$-534 Mln
ROE
-0.3 %
ROCE
-20.4 %
P/E Ratio
--
P/B Ratio
16.9
Industry P/E
--
EV/EBITDA
-59.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4
Face value
--
Shares outstanding
188,663,008
CFO
$-1,412.69 Mln
EBITDA
$-1,868.17 Mln
Net Profit
$-2,169.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Seagen (SGEN)
| 78.0 | 6.8 | 10.8 | 72.9 | 5.0 | 34.3 | 19.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P 100#
| -7.2 | -4.1 | -6.5 | 18.4 | 19.6 | 12.2 | 13.4 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Seagen (SGEN)
| -16.9 | -11.7 | 53.3 | 101.7 | 5.9 | 1.4 | 17.6 |
|
S&P 100
| -22.1 | 27.6 | 19.3 | 29.5 | -5.8 | 19.3 | 8.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Seagen (SGEN)
|
228.7 | 43,154.8 | 2,300.4 | -750.2 | -35.0 | -28.5 | -- | 16.9 |
| 0.7 | 16.2 | 0.4 | -60.9 | -3,716.2 | -- | -- | 17.3 | |
| 3.4 | 93.0 | 1.0 | -27.1 | -2,935.3 | -125.1 | -- | 6.0 | |
| 3.5 | 8.2 | 0.0 | -39.4 | -- | -54.6 | -- | 0.4 |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma... or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc. Read more
Chief Financial Officer
Mr. Todd E. Simpson
Chief Financial Officer
Mr. Todd E. Simpson
Headquarters
Bothell, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Seagen Inc (SGEN) is $228.74 (NASDAQ) as of 22-Dec-2023 09:30 EDT. Seagen Inc (SGEN) has given a return of 4.96% in the last 3 years.
Since, TTM earnings of Seagen Inc (SGEN) is negative, P/E ratio is not available.
The P/B ratio of Seagen Inc (SGEN) is 16.92 times as on 22-Dec-2023, a 329 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-39.18
|
8.53
|
|
2021
|
-41.97
|
9.23
|
|
2020
|
53.10
|
9.34
|
|
2019
|
-322.50
|
10.87
|
|
2018
|
-40.76
|
7.12
|
The 52-week high and low of Seagen Inc (SGEN) are Rs -- and Rs -- as of 02-Apr-2026.
Seagen Inc (SGEN) has a market capitalisation of $ 43,155 Mln as on 22-Dec-2023. As per SEBI classification, it is a Large Cap company.
Before investing in Seagen Inc (SGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.